nodes	percent_of_prediction	percent_of_DWPC	metapath
Gallamine Triethiodide—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.063	0.0739	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0537	0.063	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNA4—attention deficit hyperactivity disorder	0.0501	0.0587	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNA4—attention deficit hyperactivity disorder	0.0443	0.0519	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—attention deficit hyperactivity disorder	0.0355	0.0416	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—COMT—attention deficit hyperactivity disorder	0.0302	0.0354	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—attention deficit hyperactivity disorder	0.03	0.0352	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—forebrain—attention deficit hyperactivity disorder	0.0236	0.16	CbGeAlD
Gallamine Triethiodide—ACHE—Biogenic Amine Synthesis—COMT—attention deficit hyperactivity disorder	0.0183	0.0214	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Biogenic Amine Synthesis—MAOA—attention deficit hyperactivity disorder	0.0181	0.0213	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.0164	0.0193	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.0162	0.019	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRQ—attention deficit hyperactivity disorder	0.0159	0.0187	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0158	0.0185	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0155	0.0181	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—forebrain—attention deficit hyperactivity disorder	0.0141	0.0954	CbGeAlD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0133	0.0156	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.0131	0.0154	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.013	0.0152	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—nervous system—attention deficit hyperactivity disorder	0.0128	0.0868	CbGeAlD
Gallamine Triethiodide—ACHE—midbrain—attention deficit hyperactivity disorder	0.0126	0.0852	CbGeAlD
Gallamine Triethiodide—CHRNA2—central nervous system—attention deficit hyperactivity disorder	0.0123	0.0836	CbGeAlD
Gallamine Triethiodide—CHRNA2—cerebellum—attention deficit hyperactivity disorder	0.012	0.0817	CbGeAlD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.012	0.0141	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.0119	0.0806	CbGeAlD
Gallamine Triethiodide—ACHE—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.0117	0.0137	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0107	0.0125	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—brain—attention deficit hyperactivity disorder	0.00978	0.0664	CbGeAlD
Gallamine Triethiodide—ACHE—cerebellum—attention deficit hyperactivity disorder	0.00971	0.0659	CbGeAlD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.00937	0.011	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00918	0.0108	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.00901	0.0106	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.00871	0.0102	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.00844	0.00989	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.00829	0.00973	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.00819	0.00961	CbGpPWpGaD
Gallamine Triethiodide—ACHE—brain—attention deficit hyperactivity disorder	0.00789	0.0535	CbGeAlD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.00788	0.00924	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00763	0.0518	CbGeAlD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.00763	0.00895	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00741	0.00869	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00735	0.0498	CbGeAlD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00732	0.00859	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00709	0.00832	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA4—attention deficit hyperactivity disorder	0.00702	0.00823	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00697	0.00818	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00688	0.00807	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00641	0.00752	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00613	0.0072	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—brain—attention deficit hyperactivity disorder	0.00583	0.0396	CbGeAlD
Gallamine Triethiodide—ACHE—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.00568	0.00666	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00534	0.00627	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00528	0.00619	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.0049	0.00575	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00489	0.00574	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.0047	0.00551	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00449	0.00527	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.00437	0.00513	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.00404	0.00474	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.00379	0.00445	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00376	0.00441	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00375	0.0044	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.00372	0.00436	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00369	0.00433	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00364	0.00427	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00335	0.00393	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.00328	0.00385	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00326	0.00383	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.00314	0.00369	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00305	0.00357	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00303	0.00356	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00298	0.0035	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00298	0.0035	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00296	0.00348	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00291	0.00341	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00285	0.00334	CbGpPWpGaD
Gallamine Triethiodide—CHRNA2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00283	0.00332	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.0027	0.00317	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.0027	0.00317	CbGpPWpGaD
Gallamine Triethiodide—ACHE—ATF-2 transcription factor network—EP300—attention deficit hyperactivity disorder	0.00262	0.00307	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00261	0.00306	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00256	0.003	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.00251	0.00295	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00251	0.00295	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.0025	0.00293	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00237	0.00278	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.00232	0.00273	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.0023	0.0027	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.00229	0.00268	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.00228	0.00268	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00223	0.00261	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00207	0.00243	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00207	0.00243	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00199	0.00233	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.00195	0.00229	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00195	0.00228	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00189	0.00222	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00183	0.00214	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00181	0.00212	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00177	0.00208	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—COMT—attention deficit hyperactivity disorder	0.00176	0.00207	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.00175	0.00206	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00175	0.00205	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.00172	0.00202	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.0017	0.002	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00168	0.00197	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00167	0.00196	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00163	0.00191	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.0016	0.00188	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00159	0.00186	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00158	0.00185	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00155	0.00182	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.00154	0.00181	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00152	0.00178	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00147	0.00173	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00144	0.00169	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00139	0.00164	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00137	0.00161	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00135	0.00159	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00135	0.00158	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00126	0.00148	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00118	0.00138	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.00132	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.0011	0.00129	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0011	0.00129	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00106	0.00125	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00106	0.00124	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00104	0.00122	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00103	0.00121	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00103	0.00121	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00102	0.0012	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00102	0.0012	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000999	0.00117	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000961	0.00113	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000898	0.00105	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000883	0.00104	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000817	0.000958	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000763	0.000895	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000732	0.000859	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000732	0.000859	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00072	0.000845	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000701	0.000823	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000693	0.000812	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000673	0.000789	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00067	0.000785	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000667	0.000782	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00062	0.000727	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000605	0.00071	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000603	0.000707	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.0006	0.000704	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00059	0.000692	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00059	0.000692	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000585	0.000686	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000583	0.000683	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000579	0.000679	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000563	0.00066	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000557	0.000654	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000545	0.000639	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000543	0.000637	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000536	0.000628	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000529	0.000621	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000493	0.000578	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—COMT—attention deficit hyperactivity disorder	0.000444	0.00052	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00044	0.000517	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000427	0.000501	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000409	0.00048	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.00038	0.000446	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000358	0.000419	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000345	0.000405	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000332	0.00039	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000322	0.000378	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000317	0.000371	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000313	0.000367	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000291	0.000342	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000204	0.000239	CbGpPWpGaD
Gallamine Triethiodide—ACHE—Metabolism—EP300—attention deficit hyperactivity disorder	0.00019	0.000223	CbGpPWpGaD
Gallamine Triethiodide—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000108	0.000127	CbGpPWpGaD
